Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
Why it matters: U.S. patients and insurers face higher risk as 60‑90 % of generic drugs depend on Chinese chemicals, while Chinese firms capture $137 billion in licensing revenue, reshaping global pharma power.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- China' biopharmaceutical industry surged from near irrelevance to dominance within three years, per a December 2025 National Security Commission on Emerging Biotechnology report.
- National Security Commission on Emerging Biotechnology reports that global pharmaceutical spending on licensed Chinese drug assets rose from $9 billion in 2020 to over $137 billion by 2025, with $50 billion in deals in early 2026.
- U.S. generic drug market relies on Chinese active ingredients for an estimated 60 % of the market, with some estimates reaching 80‑90 %.
- Food and Drug Administration does not formally track the origin of active ingredients, and many U.S. drugs are imported from India, which sources precursors from China.
- Council on Foreign Relations working group chair argues that U.S. pharma executives are facilitating the industry’s own erosion by allowing Chinese dominance.
